PTC Therapeutics (PTCT) Stock Research

Over a week ago

PTC Therapeutics price target raised by $1 at BofA

PTCT

Jul 31, 8:28 AM

PTC Therapeutics price target raised by $11 at Morgan Stanley

PTCT

Jul 31, 7:44 AM

PTC Therapeutics price target raised by $13 at Wells Fargo, here's why

PTCT

Jul 31, 6:28 AM

PTC Therapeutics raises 2026 revenue view to $1.18B-$1.28B from $1.08B-$1.18B

PTCT

Jul 30, 4:09 PM

PTC Therapeutics reports Q2 EPS 92c, consensus 34c

PTCT

Jul 30, 4:07 PM

PTC Therapeutics price target lowered by $2 at Wells Fargo, here's why

PTCT

Jul 20, 6:42 AM

PTC Therapeutics price target raised by $6 at Cantor Fitzgerald, here's why

PTCT

Jul 16, 7:09 AM

PTC Therapeutics price target raised by $2 at BofA, here's why

PTCT

Jul 15, 6:59 AM

PTC Therapeutics price target raised by $2 at JPMorgan, here's why

PTCT

Jul 13, 7:00 AM

PTC Therapeutics price target raised by $3 at RBC Capital, here's why

PTCT

Jul 7, 7:21 AM

Citizens biotech analysts hold an analyst/industry conference call

Jul 2, 3:32 PM

PTC Therapeutics files to sell $500M of Convertible Senior Notes due 2031

PTCT

Jun 15, 7:04 AM

Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls

+13

Jun 9, 9:32 AM

PTC Therapeutics assumed with Buy from Neutral at Citi

PTCT

Jun 9, 5:49 AM

Acting FDA head vows to block political interference, Endpoint News says

+23

Jun 4, 2:11 PM

FDA issues draft guidance to help accelerated cell, gene therapies for patients

+24

Jun 2, 9:40 AM

PTC Therapeutics just upgraded at Jefferies, here's why

PTCT

May 27, 8:52 AM

What You Missed On Wall Street On Tuesday

+47

May 12, 4:11 PM

Trump Trade: Trump to suspend tariff-rate quotas on beef imports

+33

May 12, 10:47 AM

Trump approves plan to fire FDA head Marty Makary, CBS reports

+13

May 11, 12:22 PM

Trump Trade: U.S. plans AI security order without required model tests

+17

May 11, 10:09 AM

PTC Therapeutics price target raised by $9 at JPMorgan, here's why

PTCT

May 11, 7:04 AM

What You Missed On Wall Street On Friday

+37

May 8, 4:21 PM

PTC Therapeutics price target raised by $2 at Morgan Stanley

PTCT

May 8, 9:24 AM

Approved Products and Commercialization Capabilities: PTC Therapeutics has successfully brought several rare disease therapies to market, such as Translarna and Emflaza, generating current revenue streams and demonstrating expertise in commercializing specialized treatments globally.

Focus on Rare Diseases and Orphan Drug Status: The company strategically targets rare and ultra-rare genetic disorders, often benefiting from orphan drug designations which can lead to extended market exclusivity, expedited regulatory pathways, and reduced competition.

Advanced Therapeutic Modalities Expertise: PTC possesses significant expertise and an active pipeline in cutting-edge areas like gene therapy and RNA-based treatments, positioning them at the forefront of innovative approaches to genetic diseases.

Clinical Trial Failure Risk: The success of PTC Therapeutics depends heavily on the favorable outcomes of its ongoing and future clinical trials for drug candidates; failure to demonstrate safety and efficacy could lead to termination of development programs.

Regulatory Approval Uncertainty Risk: Obtaining and maintaining regulatory approvals for its drug candidates is a complex and lengthy process, and delays or outright rejections by health authorities would significantly impede product commercialization.

Intense Competition Risk: PTC operates in highly competitive pharmaceutical markets for rare diseases, facing competition from companies developing similar or alternative treatments, which could impact market share and pricing.